Rivaroxaban for cancer-associated venous thromboembolism
Systematic review and meta-analysis published in Science progress (2021)
Abstract
All cancers can increase the risk of developing venous thromboembolism (VTE), and anticoagulants should be considered as an optimal treatment for patients suffering from cancer-associated VTE. However, there is still a debate about whether the new oral anticoagulant, rivaroxaban, can bring better efficacy and safety outcomes globally. Thus, this systematic review and meta-analysis was conducted to evaluate the efficacy and safety of rivaroxaban. We searched PubMed, Cochrane Central Register of Controlled Trials, Web of Science, and China National Knowledge Infrastructure for relevant published papers before 1 September 2019, with no language restrictions. The primary outcomes are defined as the recurrence of VTE. The secondary outcomes are defined as clinically relevant non-major bleeding, adverse major bleeding events, and all-cause of death. The data were analyzed by Stata with risk ratio (RR) and 95% confidence interval (CI). Four trials encompassing 1996 patients were included. Rivaroxaban reduced recurrent VTE with no significant difference (RR = 0.68, 95% CI = 0.43-1.07). Similarly, there were no significant differences in adverse major bleeding events (RR = 0.86, 95% CI = 0.37-2.00), clinically relevant non-major bleeding (RR = 1.24, 95% CI = 0.73-2.12) and all-cause mortality (RR = 0.76, 95% CI = 0.40-1.44). In a selected study population of cancer patients with VTE, rivaroxaban is as good as other anticoagulants. Further, carefully designed randomized controlled trials should be performed to confirm these results.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
A systematic review and meta-analysis of four trials encompassing 1,996 cancer patients found rivaroxaban did not significantly reduce recurrent VTE, major bleeding, non-major bleeding, or all-cause mortality compared with other anticoagulants.
Context
This systematic review and meta-analysis pooled four trials (1996 patients) comparing the direct oral anticoagulant rivaroxaban with other anticoagulants for cancer-associated VTE, finding no statistically significant differences in recurrent VTE (RR 0.68, 95% CI 0.43-1.07), major bleeding, clinically relevant non-major bleeding, or all-cause mortality, and concluding rivaroxaban is 'as good as' other agents in this population. The study examines a synthetic small-molecule oral drug; its authors themselves note the included trials were few and call for further carefully designed randomized controlled trials to confirm the findings.
Citation
Reference (Vancouver style)
Liang B, Liang Y, Zhao LZ, Zhao YX, Gu N. Rivaroxaban for cancer-associated venous thromboembolism. Sci Prog. 2021;104(2):368504211012160. doi:10.1177/00368504211012160. PMID: 33913387
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026